Mother-infant vaccination with pneumococcal polysaccharide vaccine: Persistence of maternal antibodies and responses of infants to vaccination

被引:24
作者
Holmlund, Emma [1 ]
Nohynek, Hanna [1 ]
Quiambao, Beatriz [2 ]
Ollgren, Jukka [1 ]
Kayhty, Helena [1 ]
机构
[1] Natl Inst Hlth & Welf, FI-00271 Helsinki, Finland
[2] Res Inst Trop Med, Muntinlupa 1781, Metro Manila, Philippines
关键词
23-Valent pneumococcal polysaccharide vaccine; Infant immunization; Maternal antibodies; Maternal immunization; SEROTYPE-SPECIFIC HYPORESPONSIVENESS; CONJUGATE VACCINE; NASOPHARYNGEAL CARRIAGE; ACQUIRED ANTIBODIES; 22F POLYSACCHARIDE; GAMBIAN CHILDREN; T-CELLS; IMMUNIZATION; IMMUNOGENICITY; INFECTIONS;
D O I
10.1016/j.vaccine.2011.04.068
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Protection against pneumococcal infection early in life is needed. This could be achieved by maternal vaccination or by starting infant vaccinations as early as possible. In an open controlled study, pregnant women received both 23-valent pneumococcal polysaccharide vaccine (PPV), Haemophilus influenzae type b conjugate vaccine and tetanus toxoid or tetanus toxoid alone. Infants received PPV at 7 or 17 weeks and the second dose at 3 years of age. Antibodies to six pneumococcal serotypes were measured with the non-22F and 22F enzyme immunoassays (EIA). Elevated antibody concentrations after maternal vaccination persisted in infants until 4 months of age. Infants responded to serotypes 1 and 5, but not to serotypes 68,14,18C and 19F. High maternal antibody concentrations at early age reduced the responses, but not the antibody concentrations, of infants to PPV. The percentages of infants with concentrations >0.35 mu g/ml and >1 mu g/ml were high at birth, but decreased by age during the first 10 months of life. Revaccination with PPV at 3 years of age induced a good immune response. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:4565 / 4575
页数:11
相关论文
共 50 条
  • [21] Mother-Infant Transfer of Anti-Human Papillomavirus (HPV) Antibodies following Vaccination with the Quadrivalent HPV (Type 6/11/16/18) Virus-Like Particle Vaccine
    Matys, Katie
    Mallary, Sara
    Bautista, Oliver
    Vuocolo, Scott
    Manalastas, Ricardo
    Pitisuttithum, Punee
    Saah, Alfred
    CLINICAL AND VACCINE IMMUNOLOGY, 2012, 19 (06) : 881 - 885
  • [22] Pneumococcal conjugate vaccination schedules in infants-acquisition, immunogenicity, and pneumococcal conjugate and yellow fever vaccine co-administration study
    Mackenzie, Grant A.
    Osei, Isaac
    Salaudeen, Rasheed
    Secka, Ousman
    D'Alessandro, Umberto
    Clarke, Ed
    Schmidt-Chanasit, Jonas
    Licciardi, Paul, V
    Nguyen, Cattram
    Greenwood, Brian
    Mulholland, Kim
    TRIALS, 2022, 23 (01)
  • [23] Maternal Antibodies Inhibit Neonatal and Infant Responses to Vaccination by Shaping the Early-Life B Cell Repertoire within Germinal Centers
    Vono, Maria
    Eberhardt, Christiane Sigrid
    Auderset, Floriane
    Mastelic-Gavillet, Beatris
    Lemeille, Sylvain
    Christensen, Dennis
    Andersen, Peter
    Lambert, Paul-Henri
    Siegrist, Claire-Anne
    CELL REPORTS, 2019, 28 (07): : 1773 - +
  • [24] Repeat pneumococcal polysaccharide vaccination does not impair functional immune responses among Indigenous Australians
    Licciardi, Paul V.
    Hoe, Edwin
    Toh, Zheng Quan
    Balloch, Anne
    Moberley, Sarah
    Binks, Paula
    Marimla, Rachel
    Leach, Amanda
    Skull, Sue
    Mulholland, Kim
    Andrews, Ross
    CLINICAL & TRANSLATIONAL IMMUNOLOGY, 2017, 6
  • [25] Cost Effectiveness of Pneumococcal Vaccination for Infants and Children with the Conjugate Vaccine PnC-7 in Germany
    Christa Claes
    Johann-Matthias Graf von der Schulenburg
    PharmacoEconomics, 2003, 21 : 587 - 600
  • [26] The immunomodulatory effects of measles-mumps-rubella vaccination on persistence of heterologous vaccine responses
    Zimmermann, Petra
    Perrett, Kirsten P.
    van der Klis, Fiona R. M.
    Curtis, Nigel
    IMMUNOLOGY AND CELL BIOLOGY, 2019, 97 (06) : 577 - 585
  • [27] Birth outcomes in Aboriginal mother-infant pairs from the Northern Territory, Australia, who received 23-valent polysaccharide pneumococcal vaccination during pregnancy, 2006-2011: The PneuMum randomised controlled trial
    McHugh, Lisa
    Binks, Michael
    Ware, Robert S.
    Snelling, Tom
    Nelson, Sandra
    Nelson, Jane
    Dunbar, Melissa
    Mulholland, E. Kim
    Andrews, Ross M.
    AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY, 2020, 60 (01) : 82 - 87
  • [28] Persistence of antibodies to pneumococcal conjugate vaccine compared to polysaccharide vaccine in patients with Crohn's disease - one year follow up
    Kantso, Bjorn
    Halkaer, Sofie Ingdam
    Thomsen, Ole Ostergaard
    Belard, Erika
    Gottschalck, Ida Benedikte
    Jorgensen, Charlotte Svaerke
    Krogfelt, Karen A.
    Slotved, Hans-Christian
    Ingels, Helene
    Petersen, Andreas Munk
    INFECTIOUS DISEASES, 2019, 51 (09) : 651 - 658
  • [29] Long-term impact of pneumococcal polysaccharide vaccination on nasopharyngeal carriage in children previously vaccinated with various pneumococcal conjugate vaccine regimes
    Boelsen, Laura K.
    Dunne, Eileen M.
    Lamb, Karen E.
    Bright, Kathryn
    Cheung, Yin Bun
    Tikoduadua, Lisi
    Russell, Fiona M.
    Mulholland, E. Kim
    Licciardi, Paul V.
    Satzke, Catherine
    VACCINE, 2015, 33 (42) : 5708 - 5714
  • [30] Pneumococcal conjugate vaccination schedules in infants—acquisition, immunogenicity, and pneumococcal conjugate and yellow fever vaccine co-administration study
    Grant A. Mackenzie
    Isaac Osei
    Rasheed Salaudeen
    Ousman Secka
    Umberto D’Alessandro
    Ed Clarke
    Jonas Schmidt-Chanasit
    Paul V. Licciardi
    Cattram Nguyen
    Brian Greenwood
    Kim Mulholland
    Trials, 23